Abstract
Purpose To gain insights into potential genetic factors contributing to the infant’s vulnerability to Sudden Unexpected Infant Death (SUID).
Methods Whole Genome Sequencing (WGS) was performed on 145 infants that succumbed to SUID, and 576 healthy adults. Variants were filtered by gnomAD allele frequencies and predictions of functional consequences.
Results Variants of interest were identified in 86 genes, 63.4% of our cohort. Seventy-one of these have been previously associated with SIDS/SUID/SUDP. Forty-three can be characterized as cardiac genes and are related to cardiomyopathies, arrhythmias, and other conditions. Variants in 22 genes were associated with neurologic functions. Variants were also found in 13 genes reported to be pathogenic for various systemic disorders. Variants in eight genes are implicated in the response to hypoxia and the regulation of reactive oxygen species (ROS) and have not been previously described in SIDS/SUID/SUDP. Seventy-two infants met the triple risk hypothesis criteria (Figure 1).
Conclusion Our study confirms and further expands the list of genetic variants associated with SUID. The abundance of genes associated with heart disease and the discovery of variants associated with the redox metabolism have important mechanistic implications for the pathophysiology of SUID.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was funded by the Aaron Matthew SIDS Research Guild, Seattle Childrens Research Institute, and NIH Grants R01 HL126523(awarded to J.-M.R.), P01 HL090554 (awarded to J.-M.R.)
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The IRB of Seattle Children's Research Institute gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
This manuscript was updated to clarify/condense information about the characterization of the cohort. Figure 1 has been added. Figure 2 (formerly figure 1) has been updated. Figures 3-5 (formerly figures 2-4 have been updated to replace case/control language with affected/healthy language. Figure 6 has been added. Figure 8 (formerly figure 6) has been updated. APA style has been adopted. Table 1 has been condensed. Two errors in Table 2 have been corrected: A duplicate CFTR variant was removed, and the ITGB3 variant corrected. Supplemental Table 4 has been updated.
Data Availability
The data that support the findings of this study are available on request from the corresponding author. The data are not publicly available due to privacy or ethical restrictions.